After unveiling positive results for its lead drug, sacituzumab govitecan, in breast cancer at the influential American Society of Clinical Oncology (ASCO) conference, shares in Immunomedics(NASDAQ:IMMU) rallied by as much as 14.7% today before settling in for a gain of 9.3% at 3 p.m. EDT.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,